High-Level Overview
Auricle is a medical device startup developing a breakthrough neurostimulation implant designed to restore hearing and speech understanding in patients with severe-to-profound high-frequency sensorineural hearing loss. The company targets a large, underserved population—over 3.5 million people in the U.S. alone—who no longer benefit from hearing aids but are hesitant to undergo cochlear implantation due to its invasiveness and risk of residual hearing loss. Auricle’s solution offers a reversible, minimally invasive alternative that preserves natural hearing, addressing a critical gap in the current treatment landscape. The company has already demonstrated proof-of-concept in acute human clinical studies and is advancing toward its first full clinical trial, positioning itself for rapid growth in a $1.2B market with established reimbursement pathways.
Origin Story
Auricle was co-founded in 2020 by Francis Wong and Jay Dhuldhoya during their time in the Stanford Biodesign Innovation Fellowship. Francis Wong, a UK-trained surgeon with an MBA/MPH from UC Berkeley, brings clinical expertise and startup leadership, having previously founded Outcomes, Inc. and worked at 23andMe and Castlight Health. Jay Dhuldhoya, a biomedical engineer with degrees from Columbia and Rice, has extensive experience in R&D and manufacturing of Class III medical devices. The idea for Auricle emerged from their shared recognition of the unmet need for a less invasive, reversible hearing restoration solution for patients who fall between hearing aids and cochlear implants. Early traction included two successful acute human clinical studies and a Neuroscience:Translate Award from Stanford, validating the scientific and clinical potential of their approach.
Core Differentiators
- Preservation of Natural Hearing: Unlike cochlear implants, Auricle’s device is designed to preserve residual low-frequency hearing, a major concern for patients considering invasive procedures.
- Reversible and Minimally Invasive: The implantation is less invasive and reversible, reducing patient risk and anxiety associated with permanent surgical intervention.
- Targeted High-Frequency Restoration: Focuses on restoring high-frequency hearing, which is critical for speech comprehension, a key limitation in current hearing aids.
- Proven Clinical Feasibility: Two acute human clinical studies have demonstrated the device’s efficacy, de-risking the technology for further development.
- Strong Reimbursement Pathway: The solution fits within existing healthcare reimbursement models, enabling rapid market adoption.
Role in the Broader Tech Landscape
Auricle is riding the wave of bioelectronic medicine and minimally invasive neurostimulation, a rapidly growing field that leverages electrical signals to treat chronic conditions. The timing is critical: as the global population ages, the prevalence of sensorineural hearing loss is rising, and patients are increasingly seeking less invasive, more personalized treatment options. Auricle’s approach aligns with broader trends in precision medicine and patient-centric care, offering a scalable solution that could influence the future of hearing restoration. By addressing a gap in the current standard of care, Auricle is poised to reshape the hearing loss treatment ecosystem and set a new benchmark for neurostimulation implants.
Quick Take & Future Outlook
Auricle is on the cusp of launching its first clinical trial, which could unlock significant commercial and clinical momentum. As the company advances, it is likely to attract strategic partnerships with larger medical device firms and further investment from both venture and healthcare-focused funds. The future of hearing restoration is moving toward less invasive, more personalized solutions, and Auricle is well-positioned to lead this shift. Its success could catalyze broader adoption of neurostimulation technologies across other sensory and neurological conditions, making it a pivotal player in the next generation of bioelectronic medicine.
